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‘Atherosclerosis is a chronic inﬂammatory disease
induced by cholesterol . . .’
Rudolf Virchow (1821–1902)
As suggested by Virchow more than a century ago,
inﬂammation plays a pivotal role in atherogenesis and
potentially also in the pathogenesis of hypertension and
its sequelae. As such, the current review focuses on the
role of inﬂammation in hypertension and emerging
therapeutical approaches.
Inﬂammation and cardiovascular risk
Clinical data
Over the last years chronic low-grade inﬂammation has
emerged as an important new cardiovascular risk
factor. Inﬂammatory responses within the vasculature
might release pro-inﬂammatory cytokines that increase
levels of C-reactive protein (CRP). First evidence
for a role of inﬂammation in the development of
atherosclerosis comes from studies demonstrating
its prognostic value in unstable angina [1]. The
inﬂammation hypothesis was further supported by
data from observational studies demonstrating that
CRP is a predictor of ﬁrst cardiovascular events and
might be an even stronger prognostic factor than
low-density lipoprotein (LDL)-Cholesterol for
coronary artery disease [2,3]. CRP appears to be a
stable analyte over time and has been subject to
numerous recent studies. Thus, on the basis of several
studies, the Centers for Disease Control and Prevention
and the American Heart Association recommended
using highly sensitive (hs)-CRP and implicated the rela-
tive risk categories (low, average, high), corresponding
to approximate tertiles of values (<1.0, 1.0 to 3.0 and
>3.0mg/l, respectively) for individual cardiovascular
risk assessment, in particular for those patients
presenting with an intermediate risk [4]. However,
a single inﬂammatory marker may or may not estimate
all aspects of the underlying inﬂammatory processes,
especially as they may affect cardiovascular disease
(CVD) risk, and different markers may differ in their
speciﬁcity for CVD. Indeed, there are several additional
markers with a potential role as useful predictors of
cardiovascular risk, such as serum amyloid-A, cytokines
(e.g. interleukin (IL)-6), acute phase reactants, adhe-
sion molecules and ﬁbrinogen.
Interestingly, a recent publication demonstrated that
signiﬁcant gender and race differences in CRP levels
exist which contribute to differences in cardiovascular
outcome [5]. CRP plasma levels were assessed in 2749
white and black subjects aged 30–65 years and
participating in the Dallas Heart Study. Black subjects
had higher CRP levels than white subjects and women
had higher CRP levels than men, suggesting that
overall recommendations for CRP cut-off levels
for risk assessment should be adjusted for race and
gender. The clinical relevance of CRP as a signiﬁcant
predictor of coronary artery disease (CAD) was further
challenged by Danesh et al. [6], demonstrating that
CRP was a weaker marker than traditional risk factors
like total cholesterol or smoking in the Reykjavik
prospective study. However, in the study population,
total plasma cholesterol levels were higher and CRP
levels lower than those reported in the US population.
Experimental data
Experimental data demonstrate that CRP may
exert effects on the vasculature. Indeed, CRP induces
ICAM-1, VCAM-1 and MCP-1 expression in endo-
thelial cells [7,8], upregulates angiotensin II type 1
receptors in human vascular smooth muscle cells [9]
and CRP opsonization of low-density lipoprotein (LDL)
mediates LDL uptake by macrophages [10]. CRP
inhibits the expression of NO synthase via translational
and post-translational mechanisms, resulting in reduced
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NO bioavailability, and stimulates the release of ET-1,
IL-6 and vasoconstrictive peptides in human endothelial
cells [11,12]. Interestingly, CRP levels correlate to endo-
thelial dysfunction in patients with angiographically
normal coronary arteries, established CAD and acute
coronary syndromes [13–15]. A recent publication demon-
strated speciﬁc receptors for CRP on human aortic
endothelial cells [17]. After binding to FC gamma
receptors I and II, CD64 and CD32 respectively, CRP
reduces eNOS activity and prostacyclin levels and
increases interleukin-8, ICAM-1 and VCAM-1. These
pro-inﬂammatory effects were prevented with speciﬁc
antibodies to CD32 and CD64. However, CRP elicits
potential vasoprotective effects such as endothelium-
independent vasorelaxing effects in human vessels in vitro [16].
In addition, opposing effects of native and modiﬁed
CRP have been reported. Indeed, native CRP promotes
while modiﬁed CRP attenuates the development of
atherosclerotic lesions in ApoE knockout mice [18].
Verma et al. [12] showed that CRP inhibited both
basal and vascular endothelial growth factor (VEGF)-
stimulated angiogenesis, which would in turn inhibit
plaque neovascularization. Furthermore, recent publi-
cations suggest, that CRP independent mechanisms like
azide and lipopolysaccharide, but not CRP itself,
might cause some of the observed effects on endothelial
cells [76,77].
Inﬂammation and endothelial function
Endothelial function has evolved as a surrogate for
the development and progression of atherosclerotic
disease. Indeed, impaired endothelial function, charac-
terized by reduced bioavailability of NO, has prognos-
tic value for future cardiovascular events [19] and has
been demonstrated for all established and also for
newer cardiovascular risk factors like inﬂammation.
Acute and chronic systemic inﬂammation attenuates
endothelial function. Experimental inﬂammation after
infusion of salmonella thyphi vaccine induces endo-
thelial dysfunction within 8 h in healthy volunteers [20].
Evidence for a potential role of chronic inﬂammation
in atherogenesis comes from studies in patients with
rheumatoid arthritis (RA). These patients show an
increase in both cardiovascular morbidity and morta-
lity [21]. Furthermore, striking similarities exist
between the paradigm of inﬂammation in the patho-
genesis of both atherosclerotic vascular disease and RA
[22,23]. The shared features include involvement of
cytokines, such as TNF-a and IL-6, raised concentra-
tions of CRP, ﬁbrinogen and amyloid-A, increased
local expression of adhesion molecules and endothelin-
1 [24]. These similarities suggest that inﬂammatory
mechanisms also involve the vessel wall and facilitate
the development of atherosclerotic lesions. Indeed, we
recently demonstrated early endothelial dysfunction in
patients with RA [25] providing an explanation for the
excess cardiovascular morbidity in RA patients in
whom traditional cardiovascular risk factors are
usually absent [26].
Hypertension and vascular inﬂammation
Chronic inﬂammation presents with activation of the
cyclooxygenase (COX) system, increased production
of ROS and increased synthesis of CRP and pro-
inﬂammatory cytokines, such as TNF-a and IL-6. An
increasing body of evidence suggests that low-grade
inﬂammation and oxidative stress account in part for
hypertension-induced endothelial dysfunction and that
CRP levels are associated with future development of
hypertension [27–29]. Similar results have been pro-
vided by Engstrom et al. [30], showing that increased
levels of inﬂammation-sensitive plasma proteins (ﬁbrin-
ogen, alpha1-antitrypsin, haptoglobin, ceruloplasmin
and orosomucoid) are associated with an increased
incidence of hypertension. Incident hypertension,
the initiation of antihypertensive treatment, and self-
reported systolic blood pressure of at least 140mmHg
or a diastolic blood pressure of at least 90mmHg
are increased in women with baseline CRP levels
above 3.5mg/l even after adjustment for cardiovascular
risk factors [29]. Cross-sectional analysis of more
than 15 000 women demonstrated a linear relationship
between increasing blood pressure and increasing
CRP levels [27]. During follow-up over 8 years
both parameters were strong predictors for cardio-
vascular events, and the predictive values of CRP
and elevated blood pressure in combination are
additive. Interestingly, although low-dose aspirin has
no effect on CRP levels, it has been shown to be
effective in primary prevention in men. This effect,
however, is greatest in persons with the highest levels
of hs-CRP and declines in direct relation to CRP
levels [31].
In untreated human hypertension, CRP levels have
recently been found to be increasingly dependent on
systolic blood pressure levels [32–35]. Most impor-
tantly, CRP increase is independently associated
with other classical cardiovascular risk factors [32]
and might be an independent risk factor for the
development of hypertension after correction for age,
sex, body mass index, family history of hypertension,
fasting glycemia, sedentary behaviour, and alcohol
consumption [34]. In addition, CRP is a strong risk
factor for ischaemic stroke, independent of the severity
of the underlying atherosclerotic disease [36,37]. A
recent study investigated the relationship between IL-6,
TNF-a, and hs-CRP with arterial stiffness in untreated
hypertensive patients [38]. The authors demonstrated
that hs-CRP, IL-6 and TNF-a are signiﬁcantly related
to pulse wave velocity, a marker of aortic stiffness, and
augmentation index, a manifestation of wave reﬂection,
in essential hypertension. These data suggest a pivotal
role for inﬂammation in the development of vascular
disease, hypertension in particular. However, initiation
of inﬂammatory processes expands from hypertension
towards the more complex metabolic syndrome,
including pathologic glucose and lipid levels, visceral
obesity and hypertension. Each component of the
metabolic syndrome can induce vascular inﬂammation,
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thus increasing cardiovascular risk. Therefore, a ratio-
nale for assessment of inﬂammation status and anti-
inﬂammatory treatment in addition to anti-hypertensive
treatment in atherosclerosis and hypertension is given
and may increase clinical beneﬁt.
Anti-inﬂammatory drugs and hypertension
Selective and non-selective COX-inhibitors
The impact of speciﬁc anti-inﬂammatory drugs, selec-
tive and non-selective COX-inhibitors (coxibs and
NSAIDs), on cardiovascular homeostasis and the
incidence of cardiovascular events have been discussed
intensively over the last months.
Indeed, increased cardiovascular events have been
observed with rofecoxib in the Vioxx Gastrointestinal
Outcomes Research trial (VIGOR [39]) and
Adenomatous Polyp Prevention on Vioxx (APPROVe
[40]) trial as well as with celecoxib in the Adenoma
Prevention with Celecoxib (APC) trial [41], pointing
towards a potential class effect for coxibs. This ‘class
effect’ for an increase in the risk of cardiovascular disease
is thought to be related to preferential inhibition of
prostacyclin over thromboxane and thus a tendency
towards pro-thrombosis. However, data suggest differ-
ential effects of coxibs respect to cardiovascular
risk. Thus, other mechanisms come into play and
might counterbalance this pro-thrombotic effect. These
include a differential impact on oxidative stress, inﬂam-
mation markers, endothelial function, renal function
and morphology and tissue factor expression and activity
with potential beneﬁcial effects for celecoxib but not for
rofecoxib [42–46].
In addition to putative pro-thrombotic effects of
these drugs, the impact on blood pressure levels and
blood pressure control are important. Several studies
revealed differences between commonly used drugs and
within the group of selective COX-2 inhibitors, the
coxibs. Rofecoxib is clearly associated with an increase
in blood pressure and new onset of hypertension while
celecoxib is comparable to other NSAIDs [47,48].
In patients with osteoarthritis, treatment with rofecoxib
but not celecoxib or naproxen induced a signiﬁcant
increase in 24 h systolic BP. However, a destabilization
of hypertension control occurred to some extent with
all three drugs, while this phenomenon was seen more
often in patients treated with rofecoxib than with
the other therapies [49]. Similar data come from a
recent meta-analysis of 19 randomized controlled trials
involving coxibs and non-selective NSAIDs [50].
Selective COX-2 inhibitors were associated with
blood pressure elevation compared with placebo and
nonselective NSAIDs; however, there was a higher
incidence of developing hypertension observed with
rofecoxib compared with celecoxib.
Involved mechanisms might include a disturbance of
sodium and water retention similar to that observed
with classical non-selective NSAIDs. Early studies in
healthy subjects showed that high doses of celecoxib,
rofecoxib and NSAIDs induce a slight decrease in
water, sodium and potassium excretion, but had no
impact on blood pressure levels [51,52]. In users of
NSAIDs, development of peripheral oedema and
increases in blood pressure are associated with the
development of chronic heart failure [53]. Further data
on differences between coxibs come from a large
observational study on the incidence of chronic heart
failure during COX-inhibition. In over 38 000 patients
who were started on rofecoxib, celecoxib or non-
selective NSAIDs, rofecoxib and NSAIDs showed an
adjusted rate-ratio of 1.8 and 1.4 respectively, while no
increased risk of admission for congestive heart failure
was observed for celecoxib [54].
Interestingly, ACE-inhibitors, beta blockers and
diuretics, and to a lesser extent angiotensin II receptor
blockers and calcium channel blockers, rely on the
synthesis of vasodilator prostaglandins to exert their
effects [55,56]. This is of particular interest, since
prostacyclin levels can be reduced not only with
selective COX-2 inhibitors but also with higher doses
of classical NSAIDs [57]. This might translate into
clinical practice, as recent data suggest that rofecoxib
appears to interfere with the anti-hypertensive effects of
ACE-inhibitors and beta-blockers, but not of calcium
channel blockers [47].
While anti-hypertensive treatment is known to
improve endothelial function as a surrogate for
atherosclerosis, clinical and experimental studies also
demonstrate that anti-inﬂammatory treatment has
beneﬁcial effects on vascular function. In patients
with severe CAD, treatment with celecoxib reduces
plasma levels of hs-CRP and oxidized-LDL, as markers
of low-grade chronic inﬂammation and oxidative stress.
This effect was accompanied by improved endothelial
function [42]. Similar results were obtained in patients
with arterial hypertension who were treated with
celecoxib. Endothelial function improved within 3 h
and remained so during the treatment course [43].
A comparative study of celecoxib, rofecoxib and
diclofenac on vascular function in salt-sensitive hyper-
tensive rats showed that celecoxib, but not rofecoxib
or diclofenac, improves endothelial function [44]. In addi-
tion, oxidative stress and inﬂammation markers were
reduced by celecoxib alone. In a similar model, celecoxib
improved proteinuria, renal and pre-glomerular vessel
morphology and reduced the number of macrophages
and CRP-mRNA in renal cortex of the hypertensive
animals [45].
ACE-inhibitors and angiotensin receptor blockers
Several large randomized trials demonstrated a reduc-
tion in the incidence of recurrent cardiovascular events
and mortality with ACE-inhibitor therapy [58–60].
In addition, ACE-inhibitors and angiotensin receptor
blockers exert anti-inﬂammatory effects particularly by
inhibiting pro-inﬂammatory effects of angiotensin II [61].
Olmesartan treatment signiﬁcantly reduced serum
levels of hs-CRP, TNF-a, IL-6, and monocyte chemo-
tactic protein-1 after 6 weeks of therapy in patients with
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essential hypertension, suggesting that this anti-inﬂam-
matory action of angiotensin II receptor antagonists
may contribute to their beneﬁcial cardiovascular
effects. The stimulation of cytokines by angiotensin II
seems to be mediated via an activation of nuclear
factor-kB (NF-kB) dependent pathway, which can be
blocked, by losartan and candesartan [62,63].
Statins
Statin treatment signiﬁcantly reduces the number of
cardiovascular events, particularly in secondary pre-
vention [64,65]. For better guidance of cholesterol levels
to reduce cardiovascular risk with statins, monitoring
of CRP might be helpful, because statins lower
LDL cholesterol and CRP. The relationships between
LDL cholesterol and CRP levels after treatment with
atorvastatin or pravastatin and the risk of recurrent
myocardial infarction or death from coronary causes
were evaluated among 3745 patients with acute coronary
syndromes [66]. Both statins lowered cholesterol levels,
although atorvastatin was more likely than pravastatin
to result in low levels of LDL cholesterol and CRP.
Patients who had LDL cholesterol levels of less than
70mg/dl and CRP levels of less than 1mg/l after statin
therapy had the lowest rate of recurrent events,
demonstrating that patients who have low CRP levels
after statin therapy have better clinical outcomes than
those with higher CRP levels, regardless of the resultant
level of LDL cholesterol. To further investigate the
impact of statin treatment in the primary prevention
of cardiovascular disease in patients with low LDL-
cholesterol but elevated hs-CRP levels, the JUPITER
trial has recently been initiated [67].
PPAR gamma activators
Other widely described drugs for patients with
cardiovascular risk factors like hypertension, metabolic
syndrome and type 2 diabetes, peroxysome proliferator-
activated receptor (PPAR)-alpha and -gamma acti-
vators, seem to have anti-inﬂammatory properties.
Indeed, PPAR-alpha activators like fenoﬁbrate inhibit
myocardial inﬂammation in angiotensin II-infused
and salt-induced hypertensive rats [68,69]. In a similar
model, angiotensin II-induced hypertensive rats
received the PPAR-gamma activators pioglitazone
or rosiglitazone. Both drugs reduced upregulated cell
cycle proteins and pro-inﬂammatory mediators like
NF-kB, VCAM and PECAM and improved endo-
thelial function, and attenuated blood pressure increase
and expression of angiotensin II type 1 receptors [70].
The anti-inﬂammatory effects of pioglitazone seem to
be independent of glucose control, as demonstrated
recently in a prospective study in 192 patients with type
2 diabetes [71]. Therefore, in view of the evolving
epidemic of the metabolic syndrome with arterial
hypertension and hyperglycaemia, additional effects
of drugs for the control of single components of the
metabolic syndrome are important.
Cannabinoid receptor antagonist
This might hold also for a very new class of drugs
interacting with the endocannabinoid system, the
cannabinoid-1 receptor in particular. Originally devel-
oped to help smoking cessation, rimonabant has
favourable effects on body weight, waist circumference,
insulin resistance and dyslipidaemia [72]. In normotensive
animals no effect on blood pressure levels is observed
but in hypertensive animals, rimonabant lowers blood
pressure and reduces cardiac contractility [73].
In addition, rimonabant has potent anti-inﬂammatory
activity, as demonstrated in several animalmodels [74,75].
However, data from large-scale human studies show
that effects on blood pressure are only mild and data on
impact on inﬂammation markers are as yet unavailable.
Conclusion
Inﬂammation plays a pivotal role in the development
and progression of atherosclerosis. Like other risk
factors, arterial hypertension is associated with a
pro-inﬂammatory status. However, the ‘inﬂammation
in atherosclerosis hypothesis’ remains still to be
challenged in prospective clinical trials. Indeed, unless
anti-inﬂammatory treatment strategies provide beneﬁt
for patients, inﬂammation may thus face the fate
of some other cardiovascular risk factors that,
notwithstanding their potential pathophysiological
relevance, are considered as lost in translation into
clinical practice.
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